Epigenomics AG / Key word(s): Capital Increase
29.10.2013 08:55
Dissemination of a Ad-hoc-correction according to § 15 WpHG, transmitted by
DGAP - a company of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Correction notifaction of the announcement of Epigenomics AG (Frankfurt
Prime Standard: ECX; ISIN: DE000A1K0516) according to § 15 WpHG as of
October 28, 2013 - 9:00 pm CET
Epigenomics erroneously announced yesterday its intention to increase its
share capital by up to EUR 4,136,720.00 from the authorized capital.
Instead, Epigenomics plans to increase its share capital by up to EUR
828,504,00 by issuing new shares at EUR 4.993 per share, thus raising up
to EUR 4,136,720.00 in total gross proceeds. The correct notification is:
Not for distribution in the United States
Berlin,Germany,October 28, 2013- Epigenomics AG (ISIN: DE000A1K0516)
announces that the Company's Executive Board today with the approval of the
Supervisory Board has resolved on an increase of the Company's share
capital by up to EUR 828,504 from the authorized capital,thus raising up to
EUR 4.136.720 in total gross proceeds. This capital increase follows a
previous capital increase, published via ad hoc announcement on October 27,
2013, through which the strategic partner BioChain invested into the
Company. The newly issued shares resulting from the envisagedcapital
increase will be offered against contribution in cashin a private
placementtoinstitutional investors in Europe and the U.S.. The preemptive
rights of the shareholders will be excluded. The issue price has been set
at EUR 4.993 per share andequalsthe volume-weighted average XETRA trading
price duringthe last three trading days including the day of this
announcement.
The placement of the shares is scheduled for Tuesday, October 29, 2013.
Following completion of the placement, the Supervisory and Executive Boards
of the Company are going to resolve on the final amount of shares to be
issued, such resolution to be disclosed by way of an ad hoc announcement
without undue delay.
Epigenomics AG intends to use the net proceeds from the offering to finance
its current operations and to build and strengthen the distribution
capacities for its lead product Epi proColon(R), a blood-based test for the
detection of colorectal cancer.
-End of Ad hoc-
Disclaimer
This publication is not an offer of any securities for sale or a
solicitation of an offer to purchase any securities.
This document is not an offer of securities for sale or a solicitation of
an offer to purchase securities in the United States. The shares of
Epigenomics AG (the 'Shares') have not beenregistered under the U.S.
Securities Act of 1933, as amended (the 'Securities Act') and may not be
offered or sold in the United States unless registered under the Securities
Act or pursuant to an exemption from such registration. There will be no
public offering of the Shares in the United States and the Shares will not
be registered under the Securities Act.
Contact:
Epigenomics AG
Antje Zeise CIRO
Manager IR | PR
Epigenomics AG
Phone: +49 (0) 30 24345 386
ir@epigenomics.com
www.epigenomics.com
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Epigenomics AG and its business. Such statements
involve certain known and unknown risks, uncertainties and other factors
which could cause the actual results, financial condition, performance or
achievements of Epigenomics AG to be materially different from any future
results, performance or achievements expressed or implied by such
forward-looking statements. Epigenomics AG is providing this communication
as of this date and does not undertake to update any forward-looking
statements contained herein as a result of new information, future events
or otherwise.
The information contained in this communication does not constitute nor
imply an offer to sell or transfer any product, and no product based on
this technology is currently available for sale by Epigenomics in the
United States or Canada. The analytical and clinical performance
characteristics of any Epigenomics product based on this technology which
may be sold at some future time in the U.S. have not been established.
29.10.2013 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Epigenomics AG
Kleine Präsidentenstraße 1
10178 Berlin
Germany
Phone: +49 30 24345-0
Fax: +49 30 24345-555
E-mail: ir@epigenomics.com
Internet: www.epigenomics.com
ISIN: DE000A1K0516
WKN: A1K051
Listed: Regulierter Markt in Frankfurt (Prime Standard); Freiverkehr
in Berlin, Düsseldorf, München, Stuttgart
End of Announcement DGAP News-Service
---------------------------------------------------------------------------
29. October 2013 - 0:00 (CEST)